Farther’s AUM Surges 5x Year-Over-Year, Surpassing $5B

NEW YORK, Oct. 10, 2024 /PRNewswire/ — Farther, the leading technology-centric financial advisory firm, closed a $72 million Series C funding round to expand its advisor network and enhance its wealth management platform. Co-led by CapitalG, the independent growth fund of Alphabet (Google’s parent company), and Viewpoint Ventures, this funding round elevates Farther’s post-money valuation to $542 million.

The funding comes as Farther surpasses $5 billion in assets under management (AUM), a milestone that reflects 5x year-over-year growth. This success underscores the power of Farther’s proprietary, custom-built technology – which drives operational efficiencies, boosts advisor productivity and payouts, and accelerates asset growth.

“We built Farther to enable advisors to focus on what truly matters: delivering value to their clients,” said Taylor Matthews, CEO and co-founder of Farther. “Removing operational and administrative hurdles creates growth opportunities for our advisors, and they can offer a superior experience to even more clients. This capital infusion signals strong market confidence in that vision. With this investment, we will continue enhancing Farther’s technology to set a new benchmark for wealth management advisors and clients alike.”

Seasoned advisors are drawn to Farther’s cutting-edge technology, white-glove support, and advisor-first culture. Farther’s technology enables advisors to dedicate 90% of their time to client interactions and prospecting – 4x more than is typical. That helps them simultaneously grow their books of business faster and deliver more for their clients. Free from mandatory minimums and non-compete agreements, advisors are empowered to build client bases that align with their personal goals, backed by a transparent payout structure and equity in the firm.

“At CapitalG, we take a deep, thesis-driven approach to investments. We spent years looking for companies with the potential to transform the wealth management industry. We were drawn to Farther both for its strong leadership team and for its unique business model which pairs world-class, proprietary technology with human expertise. This creates an ideal environment in which both advisors and clients flourish, and a flywheel which will continue to attract best-in-class advisors to the Farther platform,” said Jesse Wedler, general partner at CapitalG. “We look forward to helping them further scale their innovative wealth management business.”

“We’ve been impressed with how fast Farther is growing organically, especially in an industry where growth has mostly come from M&A,” said Drew Aldrich, founder and managing partner of Viewpoint Ventures. “Viewpoint’s thesis-driven strategy was purpose-built to invest in firms, like Farther, that transform human-powered markets. In our experience, attracting the best advisors to a tech-enabled platform like Farther’s leads to accelerating advantage and, ultimately, industry dominance.”

With the latest investment, Farther has raised more than $118 million in total funding. The company’s existing investor base includes Bessemer Venture Partners, Context Ventures, Cota Capital,  Khosla Ventures, Lightspeed Venture Partners, MassMutual Ventures, and Moneta Venture Capital.

About Farther

Farther is the nation’s leading technology-centric wealth management firm – empowering expert advisors with cutting-edge technology to deliver an efficient, comprehensive, and elite client experience. The fastest-growing RIA in the country, Farther manages over $5 billion in assets across 100+ wealth managers and 5,000 clients. For more information, visit https://farther.com/.

About CapitalG

CapitalG, Alphabet’s independent growth fund, invests in remarkable companies transforming the fields of enterprise infrastructure, security, and data; fintech; and consumer services and marketplaces. CapitalG partners with growth stage companies in their transition from startup to scale up through hands-on assistance from its in-house growth team and connections to Google’s engineering, product, marketing, sales and people operations experts worldwide. More than 35,000 Googlers and Alphabet leaders have engaged with CapitalG portfolio companies, including Airbnb, CrowdStrike, Databricks, Duolingo, Freshworks, Gusto, Lyft, Stripe, UiPath and Zscaler, among others. Learn more at https://capitalg.com/.

About Viewpoint Ventures

Viewpoint Ventures is a thesis-driven, late-stage venture capital firm based in New York City. The firm focuses on businesses that empower human “producers” (such as advisors, agents, and brokers) with technology and services to unlock growth. Viewpoint targets industries where producers are central, including wealth management, real estate, and insurance. Learn more at https://www.viewpoint.vc/.

SOURCE Farther

https://prnmedia.prnewswire.com/news-releases/farther-secures-72-million-series-c-from-capitalg-and-viewpoint-ventures-to-continue-revolutionizing-wealth-management-302273094.html

TREMFYA^® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn’s disease

TREMFYA^® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn’s disease, inclusive of those who are biologic-naïve and biologic-refractory 

Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA^® 

VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced TREMFYA^® (guselkumab) data in both Crohn’s disease (CD) and ulcerative colitis (UC) showing high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients (including UC patients refractory to JAK inhibitors), indicating a normal appearance of intestinal mucosa.^1,2 These subgroup analyses are from pooled data from the Phase 3 GALAXI 2 & 3 studies of TREMFYA^® in adults with moderately to severely active CD and the Phase 3 QUASAR maintenance study of TREMFYA^® in adults with moderately to severely active UC. These findings are among 19 Johnson & Johnson abstracts being presented at the United European Gastroenterology (UEG) Week 2024. TREMFYA^® is under review for the treatment of adults with moderately to severely active UC and CD by the European Medicines Agency (EMA). 

“These results show the potential of TREMFYA to offer a differentiated treatment option for patients with CD and UC, including those starting on a biologic for the first time, and those who have failed prior biologics and traditionally have been less likely to respond to other therapies,” stated Esi Lamousé-Smith, M.D., Ph.D., Vice President, Gastroenterology Disease Area Lead, Immunology, Johnson & Johnson Innovative Medicine. “TREMFYA builds upon our nearly three decades of leadership in IBD therapy and focused innovation in the IL-23 pathway to address the needs of people living with ulcerative colitis and delivering meaningful improvements in symptoms and the potential for sustained remission.” 

Endoscopic remission in biologic-naïve patients
In the pooled Phase 3 GALAXI 2 & 3 dataset, TREMFYA^® demonstrated greater rates of endoscopic remission compared to ustekinumab at Week 48 in biologic-naïve patients with CD. Endoscopic remission was achieved in 44% of patients treated with TREMFYA^® 100 mg every eight weeks (q8w) subcutaneous (SC) injection and 46.1% of patients treated with TREMFYA^® 200 mg every four weeks (q4w) SC injection, versus 29.8% of patients treated with ustekinumab.¹ 

In the Phase 3 QUASAR study, TREMFYA^® demonstrated greater rates of endoscopic remission compared to placebo at Week 44 in biologic/JAK inhibitor-naïve patients with UC. Endoscopic remission was achieved in 38.1% of patients treated with TREMFYA^® 100 mg q8w SC injection and 41.7% of patients treated with TREMFYA^® 200 mg q4w SC injection, versus 20.4% of patients treated with placebo.² 

Endoscopic remission in patients with a history of inadequate response or intolerance to biologics/JAK inhibitors 
In the pooled Phase 3 GALAXI 2 & 3 dataset, TREMFYA^® demonstrated greater rates of endoscopic remission compared to ustekinumab at Week 48 in biologic-refractory patients with CD. Endoscopic remission was achieved in 28.1% of patients treated with TREMFYA^® 100 mg q8w SC injection and 28.6% of patients treated with TREMFYA^® 200 mg q4w SC injection, versus 20.5% of patients treated with ustekinumab.¹

In the Phase 3 QUASAR study, TREMFYA^® demonstrated greater rates of endoscopic remission compared to placebo at Week 44 in biologic/JAK inhibitor-refractory patients with UC. Endoscopic remission was achieved in 31.2% of patients treated with TREMFYA^® 100 mg q8w SC injection and 23.9% of patients treated with TREMFYA^® 200 mg q4w SC injection, versus 8% of patients treated with placebo.² 

Results from these studies reinforce the well-established safety profile of TREMFYA^® including in the treatment of patients with UC and CD.

For a full list of abstracts presented please click here. 

TREMFYA^® received U.S. Food and Drug Administration (FDA) approval in September 2024 for the treatment of adults with moderately to severely active UC and an application for the treatment of moderately to severely active CD is currently under FDA review. Regulatory applications seeking approval of TREMFYA^® for the treatment of adults with moderately to severely active UC and for the treatment of adults with moderately to severely active CD have been submitted in Europe.

ABOUT THE GALAXI PROGRAM (NCT03466411)

GALAXI is a randomized, double-blind, placebo-controlled, active-controlled (ustekinumab), global, multicenter Phase 2/3 program designed to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease with inadequate response/intolerance to conventional therapies (corticosteroids or immunomodulators) and/or biologics (TNF antagonists or vedolizumab).³ GALAXI includes a Phase 2 dose-ranging study (GALAXI 1) and two independent, identically designed confirmatory Phase 3 studies (GALAXI 2 and 3).¹ Each GALAXI study employed a treat-through design in which participants remained on the treatment to which they were initially randomized and includes a long-term extension study that will assess clinical, endoscopic, and safety outcomes with guselkumab through a total of five years. Patients received guselkumab 200 mg intravenous induction at Weeks 0, 4 and 8 followed by guselkumab 200 mg subcutaneous maintenance every 4 weeks; or guselkumab 200 mg intravenous induction at Weeks 0, 4 and 8, followed by guselkumab 100 mg subcutaneous maintenance every 8 weeks; or a biologic active control; or placebo. Participants randomized to placebo were able to receive ustekinumab if clinical response was not met at Week 12. Of the 873 individuals pooled across the GALAXI 2 & 3 dataset, 456 (52 percent) had prior history of inadequate response to biologics, 365 (41.8 percent) were biologic-naïve and 52 (6 percent) were biologic experienced without documented inadequate response or intolerance.¹ The GALAXI 2 and GALAXI 3 studies were the first-ever double-blind registrational head-to-head clinical trials to demonstrate superiority versus ustekinumab in CD. Data from GALAXI 2 & 3 showed guselkumab was superior to ustekinumab in all pooled endoscopic endpoints.

ABOUT THE QUASAR STUDY (NCT04033445) 

QUASAR is a randomized, double-blind, placebo-controlled, parallel group, multicenter, Phase 2b/3 program designed to evaluate the efficacy and safety of guselkumab in adults with moderately to severely active ulcerative colitis who had an inadequate response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab) and/or JAK inhibitors (tofacitinib).⁴ QUASAR included a Phase 2b dose-ranging induction study, a confirmatory Phase 3 induction study, and a Phase 3 randomized withdrawal maintenance study. In the induction study, patients received either guselkumab 200 mg or placebo by intravenous infusion at Week 0, Week 4, and Week 8. In the maintenance study, patients received a subcutaneous maintenance regimen of either TREMFYA 100 mg every 8 weeks, guselkumab 200 mg every 4 weeks, or placebo. Efficacy, safety, pharmacokinetics, immunogenicity, and biomarkers are assessed at specified time points. Of the 568 individuals included in the QUASAR maintenance study, 240 (42.3 percent) had a history of inadequate response or intolerance to biologics or JAK inhibitors, 309 (54.4 percent) were biologic/JAK inhibitor naïve, and 19 (3.3 percent) were biologic/JAK inhibitor experienced without documented inadequate response or intolerance.³

ABOUT CROHN’S DISEASE

Crohn’s disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.^5,6 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.⁷ Symptoms of Crohn’s disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever.

ABOUT ULCERATIVE COLITIS 

Ulcerative colitis (UC) is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus. It is the result of the immune system’s overactive response.⁸ Symptoms vary but may typically include loose and more urgent bowel movements, rectal bleeding or bloody stool, persistent diarrhea, abdominal pain, loss of appetite, weight loss, and fatigue. People with UC also have increased rates of depression.⁶ 

ABOUT TREMFYA^® (guselkumab)

Developed by Johnson & Johnson, TREMFYA^® is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cell that produce IL-23). Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.

TREMFYA^® is a prescription medicine approved in the U.S. to treat:

• adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
• adults with active psoriatic arthritis.
• adults with moderately to severely active ulcerative colitis.⁹

TREMFYA^® is approved Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis and for the treatment of adults with active psoriatic arthritis. 

Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA^®. For more information, visit: www.tremfya.com.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA^® (guselkumab)?

TREMFYA^® is a prescription medicine that may cause serious side effects, including:

• Serious Allergic Reactions. Stop using TREMFYA^® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

• Infections. TREMFYA^® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA^® and may treat you for TB before you begin treatment with TREMFYA^® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA^®.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

Do not take TREMFYA^® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA^®.

Before using TREMFYA^®, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about TREMFYA^®?”
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA^®.
• are pregnant or plan to become pregnant. It is not known if TREMFYA^® can harm your unborn baby.
  Pregnancy Registry: If you become pregnant during treatment with TREMFYA^®, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA^®. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu. The purpose of this registry is to collect information about the safety of TREMFYA^® during pregnancy.
• are breastfeeding or plan to breastfeed. It is not known if TREMFYA^® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA^®?

TREMFYA^® may cause serious side effects. See “What is the most important information I should know about TREMFYA^®?”

The most common side effects of TREMFYA^® include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.

These are not all the possible side effects of TREMFYA^®. Call your doctor for medical advice about side effects.

Use TREMFYA^® exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide, for TREMFYA^® and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Dosage Forms and Strengths: TREMFYA^® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA^® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion. 

ABOUT STELARA^® (ustekinumab)
STELARA^® (ustekinumab), a human interleukin (IL)-12 and IL-23 antagonist, is a prescription medicine approved in the United States to treat:

• adults and children 6 years and older with moderate to severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
• adults and children 6 years and older with active psoriatic arthritis.
• adults 18 years and older with moderately to severely active Crohn’s disease.
• adults 18 years and older with moderately to severely active ulcerative colitis.¹⁰

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to STELARA^®.

IMPORTANT SAFETY INFORMATION

STELARA^® is a prescription medicine that affects your immune system. STELARA^® can increase your chance of having serious side effects including:

Serious Infections
STELARA^® may lower your ability to fight infections and may increase your risk of infections. While taking STELARA^®, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

• Your doctor should check you for TB before starting STELARA^® and watch you closely for signs and symptoms of TB during treatment with STELARA^®.
• If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA^®.

You should not start taking STELARA^® if you have any kind of infection unless your doctor says it is okay.

Before starting STELARA^®, tell your doctor if you:

• think you have an infection or have symptoms of an infection such as:
  • fever, sweats, or chills
  • muscle aches
  • cough
  • shortness of breath
  • blood in phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinate more often than normal
  • feel very tired

• are being treated for an infection or have any open cuts.
• get a lot of infections or have infections that keep coming back.
• have TB, or have been in close contact with someone with TB.

After starting STELARA^®, call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. STELARA^® can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL–12) and interleukin 23 (IL–23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA^® may also be more likely to get these infections.

Cancers

STELARA^® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA^®. Tell your doctor if you have any new skin growths.

Posterior Reversible Encephalopathy Syndrome (PRES)

PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious Allergic Reactions

Serious allergic reactions can occur. Stop using STELARA^® and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Lung Inflammation

Cases of lung inflammation have happened in some people who receive STELARA^® and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn’t go away during treatment with STELARA^®.

Before receiving STELARA^®, tell your doctor about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed above for serious infections, cancers, or PRES.
• ever had an allergic reaction to STELARA^® or any of its ingredients. Ask your doctor if you are not sure.
• are allergic to latex. The needle cover on the prefilled syringe contains latex.
• have recently received or are scheduled to receive an immunization (vaccine). People who take STELARA^® should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receiving STELARA^® or one year after you stop receiving STELARA^®.
• have any new or changing lesions within psoriasis areas or on normal skin.
• are receiving or have received allergy shots, especially for serious allergic reactions.
• receive or have received phototherapy for your psoriasis.
• are pregnant or plan to become pregnant. It is not known if STELARA^® can harm your unborn baby. You and your doctor should decide if you will receive STELARA^® if you are breastfeeding or plan to breastfeed. It is thought that STELARA^® passes into your breast milk.
• talk to your doctor about the best way to feed your baby if you receive STELARA^®.

Tell your doctor about all the medicines you take, including prescription and over–the–counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed STELARA^®:

• Use STELARA^® exactly as your doctor tells you to.
• STELARA^® is intended for use under the guidance and supervision of your doctor. In children 6 years and older, it is recommended that STELARA^® be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of STELARA^® at home, you should receive training on the right way to prepare and inject STELARA^®. Your doctor will determine the right dose of STELARA^® for you, the amount for each injection, and how often you should receive it. Do not try to inject STELARA^® yourself until you or your caregiver have been shown how to inject STELARA^® by your doctor or nurse.

Common side effects of STELARA^® include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with STELARA^®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please click to read the full Prescribing Information and Medication Guide for STELARA^® and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1–800–FDA–1088.

ABOUT JOHNSON & JOHNSON

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen-Cilag International NV are Johnson & Johnson companies.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA^®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen-Cilag International NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen-Cilag International NV nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Source: Johnson & Johnson

¹ Danese S, et al. Week 48 efficacy of guselkumab and ustekinumab in Crohn’s disease based on prior response/exposure to biologic therapy: Results from the GALAXI 2 & 3 Phase 3 Studies. Poster presentation (Abstract MP672) at United European Gastroenterology Week 2024. October 2024.
² Allegretti JR, et al. The efficacy of maintenance treatment with guselkumab in patients with moderately to severely active ulcerative colitis: Phase 3 QUASAR maintenance study results at Week 44 by biologic/Janus kinase inhibitor history. Oral presentation (Abstract OP082) at United European Gastroenterology Week 2024. October 2024.
³ National Institutes of Health: Clinicaltrials.gov. A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). Identifier: NCT03466411. Available at: https://clinicaltrials.gov/study/NCT03466411. Accessed September 2024.
⁴ National Institutes of Health: Clinicaltrials.gov. A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR). Identifier: NCT04033445. https://classic.clinicaltrials.gov/ct2/show/NCT04033445. Accessed September 2024.
⁵ Crohn’s & Colitis Foundation. Overview of Crohn’s disease. Available at: www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed September 2024.
⁶ Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
⁷ Crohn’s & Colitis Foundation. What is Crohn’s disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed September 2024.
⁸ Crohn’s & Colitis Foundation. What is ulcerative colitis? Available at: https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis. Accessed April 2024.
⁹ TREMFYA^® Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf Accessed September 2024.
¹⁰ STELARA® Prescribing information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf Accessed September 2024.

SOURCE Johnson & Johnson

https://prnmedia.prnewswire.com/news-releases/tremfya-guselkumab-demonstrates-impressive-results-across-biologic-naive-and-biologic-refractory-patients-in-crohns-disease-and-ulcerative-colitis-302272206.html

New research reveals high stigma and misunderstanding of a treatable medical condition

WASHINGTON, Oct. 10, 2024 /PRNewswire/ — On Saturday, October 19, at 8:00 a.m., an event to raise awareness about addiction and mobilize Washington, D.C.-area residents to end addiction stigma will be held at The Wharf at 101 District Square SW Washington, D.C. 20024. The event, organized by the national nonprofit Shatterproof and supported by local companies and community-based organizations, is a walk and rally for those impacted by substance use disorder (SUD) to unite and address the pervasive shaming and judgment toward people with this medical condition. 

Registration is still open to participate. Visit www.Shatterproofwalk.org to register today. 

“Everybody knows someone impacted by addiction, whether it be a family member, friend, neighbor or co-worker, and it is time we end the silence, stop the judgment and shame, and bring addiction out of the shadows,” said Kirsten Seckler, chief marketing officer for Shatterproof. “Shatterproof is here to convene the many people who have been impacted and the many organizations that are making a difference locally. The Shatterproof Walk to End Addiction Stigma is a launching point for us to continue raising society’s consciousness around this health condition.” 

In the U.S., nearly 49 million people ages 12 and older have substance use disorder and new data indicates that we have lost the lives of 2,000 Washington, D.C.-area residents in the past five years due to substance use disorder. At the same time, the majority of U.S. adults demonstrate high levels of addiction stigma. This is according to new data that Shatterproof released as a part of a recent report called the Shatterproof Addiction Stigma Index, one of the most comprehensive measurement tools designed to-date, which assesses attitudes about substance use and people who have substance use disorder. 

Addiction stigma is a set of unfair, negative and often discriminatory beliefs directed toward and experienced by individuals with substance use disorder. Data in the Washington, D.C.-area specifically shows that residents state the following: 

• 75% don’t believe a person with SUD is experiencing a chronic medical illness. 
• 67% are unwilling to have a person with SUD marry into their family. 
• 57% of residents are unwilling to hire a person with SUD. 
• 51% of residents are unwilling to have a person with SUD as a close friend. 
• 49% of residents are unwilling to move next door to a person with SUD. 

Addiction stigma clouds the nation’s ability to coalesce around meaningful solutions, including treatment, harm reduction, and recovery supports and services. 

The Shatterproof Walk to End Addiction Stigma is a gathering place for all those who have been impacted by addiction. The event will honor those who have been lost to addiction, will celebrate those who are successfully managing their substance use disorder, and will rally the community to support those who are living with addiction. 

This year’s Shatterproof Walk is sponsored by Abbott, iHeart/HOT 99.5, HEI Hotels, Hilton, JPMorgan Chase, and NBC4. 

In addition to attending the walk event, anyone can make a difference and reduce stigma. 

Educate yourselves and others. 

Seek information about SUD, know how to identify and respond to an overdose, and learn about the resources available. Visit https://www.shatterproof.org/find-help for trusted guidance.

Share your story. 

Stories connect us all and people can be part of the movement to end addiction stigma by sharing how substance use has impacted their lives. Share your story: https://www.shatterproof.org/storyshare

ABOUT SHATTERPROOF: 

Shatterproof is a national nonprofit organization dedicated to transforming the addiction treatment system in the U.S. Shatterproof is focused on guiding society, especially families, through the complexities of a substance use disorder; informing the public on prevention, treatment and recovery from addiction; and educating the public to reduce addiction stigma to ensure that people who use substances or have a substance use disorder can live healthy and fulfilled lives. Find Shatterproof on Facebook, X and YouTube: @ShatterproofHQ or follow them on Instagram: @weareshatterproof. To learn more, visit www.Shatterproof.org.

SOURCE Shatterproof

https://prnmedia.prnewswire.com/news-releases/washington-dc-area-residents-unite-to-end-addiction-stigma-at-upcoming-shatterproof-event-302272193.html

IRVINE, Calif., Oct. 10, 2024 /PRNewswire/ — ATTOM, a leading curator of land, property data, and real estate analytics, today released its Q3 2024 U.S. Foreclosure Market Report, which shows a total of 87,108 U.S. properties with a foreclosure filings during the third quarter of 2024, down 2 percent from the previous quarter and down 13 percent from a year ago.

The report also shows a total of 29,668 U.S. properties with foreclosure filings in September 2024, down 2 percent from the previous month and down 19 percent from a year ago.

“While we are seeing a decrease in foreclosure starts and repossessions, it’s crucial to remain vigilant, as any economic disruptions or changes in interest rates could shift the current trend,” said Rob Barber, CEO of ATTOM. “Moving forward, we anticipate foreclosure levels will stay relatively low, but there could be localized increases in areas struggling with affordability or other market pressures.”

Foreclosure starts decrease nationwide
A total of 62,380 U.S. properties started the foreclosure process in Q3 2024, down less than 1 percent from the previous quarter and down 10 percent from a year ago.

States that had 1,000 or more foreclosures starts in Q3 2024 and saw the greatest annual decrease included, North Carolina (down 44 percent); Georgia (down 29 percent); Maryland (down 22 percent); New Jersey (down 20 percent); and South Carolina (down 19 percent).

U.S. Foreclosure Starts

Those major metros with a population of 200,000 or more that had the greatest number of foreclosures starts in Q3 2024 included, New York, New York (3,776 foreclosure starts); Chicago, Illinois (3,231 foreclosure starts); Los Angeles, CA (2,166 foreclosure starts); Miami, FL (2,142 foreclosure starts); and Houston, Texas (1,791 foreclosure starts).

Highest foreclosure rates in Illinois, Nevada, and Florida
Nationwide one in every 1,618 housing units had a foreclosure filing in Q3 2024. States with the highest foreclosure rates were Illinois (one in every 904 housing units with a foreclosure filing); Nevada (one in every 922 housing units); Florida (one in every 971 housing units); Delaware (one in every 1,060 housing units); and South Carolina (one in every 1,069 housing units).

Among 224 metropolitan statistical areas with a population of at least 200,000, those with the highest foreclosure rates in Q3 2024 were Lakeland, Florida (one in 610 housing units); Provo, Utah (one in every 647 housing units); Macon, Georgia (one in every 649 housing units); Columbia, South Carolina (one in every 663 housing units); and Atlantic City, New Jersey (one in every 766 housing units).

U.S. Historical Total Foreclosure Activity

Other major metros with a population of at least 1 million and foreclosure rates in the top 15 highest nationwide, include Chicago, Illinois (one in every 775 housing units); Las Vegas, Nevada (one in every 796 housing units); Cleveland, Ohio (one in every 819 housing units); Orlando, Florida (one in every 859 housing units); and Riverside, California (one in every 867 housing units).

Bank repossessions decrease 12 percent from last year
Lenders repossessed 8,795 U.S. properties through foreclosure (REO) in Q3 2024, up 1 percent from the previous quarter but down 12 percent from a year ago.

U.S. Completed Foreclosures (REOs)

Those states that had the greatest number of REOs in Q3 2024 were California (852 REOs); Pennsylvania (715 REOs); New York (670 REOs); Illinois (668 REOs); and Michigan (559 REOs).

Average time to foreclose increases 6 percent from last year
Properties foreclosed in Q3 2024 had been in the foreclosure process for an average of 815 days. This remains the same from the previous quarter but represents a 6 percent increase from the same time last year, continuing an upward trajectory since Q3 2023.

Average Days to Complete Foreclosure

States with the longest average foreclosure timelines for homes foreclosed in Q3 2024 were Louisiana (3,520 days); Hawaii (2,531 days); New York (2,087 days); Rhode Island (1,880 days); and Georgia (1,876 days).

States with the shortest average foreclosure timelines for homes foreclosed in Q3 2024 were New Hampshire (165 days); Minnesota (172 days); Texas (181 days); Michigan (189 days); and Montana (248 days).

September 2024 Foreclosure Activity High-Level Takeaways

• Nationwide in September 2024, one in every 4,750 properties had a foreclosure filing.
• States with the highest foreclosure rates in September 2024 were Illinois (one in every 2,494 housing units with a foreclosure filing); Florida (one in every 2,670 housing units); Delaware (one in every 2,720 housing units); Nevada (one in every 2,735 housing units); and Indiana (one in every 3,159 housing units).
• 19,763 U.S. properties started the foreclosure process in September 2024, down 5 percent from the previous month and down 21 percent from September 2023.
• Lenders completed the foreclosure process on 2,624 U.S. properties in September 2024, down 9 percent from the previous month and down 21 percent from September 2023.

Report methodology
The ATTOM U.S. Foreclosure Market Report provides a count of the total number of properties with at least one foreclosure filing entered into the ATTOM Data Warehouse during the month and quarter. Some foreclosure filings entered into the database during the quarter may have been recorded in the previous quarter. Data is collected from more than 3,000 counties nationwide, and those counties account for more than 99 percent of the U.S. population. ATTOM’s report incorporates documents filed in all three phases of foreclosure: Default — Notice of Default (NOD) and Lis Pendens (LIS); Auction — Notice of Trustee Sale and Notice of Foreclosure Sale (NTS and NFS); and Real Estate Owned, or REO properties (that have been foreclosed on and repurchased by a bank). For the annual, midyear and quarterly reports, if more than one type of foreclosure document is received for a property during the timeframe, only the most recent filing is counted in the report. The annual, midyear, quarterly and monthly reports all check if the same type of document was filed against a property previously. If so, and if that previous filing occurred within the estimated foreclosure timeframe for the state where the property is located, the report does not count the property in the current year, quarter or month.

About ATTOM

ATTOM provides premium property data and analytics that power a myriad of solutions that improve transparency, innovation, digitization and efficiency in a data-driven economy. ATTOM multi-sources property tax, deed, mortgage, foreclosure, environmental risk, natural hazard, and neighborhood data for more than 155 million U.S. residential and commercial properties covering 99 percent of the nation’s population. A rigorous data management process involving more than 20 steps validates, standardizes, and enhances the real estate data collected by ATTOM, assigning each property record with a persistent, unique ID — the ATTOM ID. The 30TB ATTOM Data Warehouse fuels innovation in many industries including mortgage, real estate, insurance, marketing, government and more through flexible data delivery solutions that include ATTOM Cloud, bulk file licenses, property data APIs, real estate market trends, property navigator and more. Also, introducing our newest innovative solution, making property data more readily accessible and optimized for AI applications– AI-Ready Solutions. 

Media Contact:
Megan Hunt
megan.hunt@attomdata.com 

Data and Report Licensing:
datareports@attomdata.com

SOURCE ATTOM

https://prnmedia.prnewswire.com/news-releases/us-foreclosure-activity-decreases-in-q3-2024-302272305.html

Gillian Riley to Retire After 30+ year Career at Scotiabank

TORONTO, Oct. 9, 2024 /CNW/ – Scotiabank today announced the planned retirement of Gillian Riley, President and CEO of Tangerine after a 31-year career with the Bank. Gillian will stay on as Strategic Advisor until December 31, 2024 and as Chair of the Board of Roynat Capital. Scotiabank also announced the appointment of Terri-Lee Weeks to the role of President and CEO, Tangerine, effective November 1, 2024.

Gillian Riley joined Scotiabank in 1994 and has held senior executive positions in Commercial Banking, Small Business, Retail Banking and Wealth Management as well as Executive Vice President of Commercial Banking and, most recently, President and CEO of Tangerine for the last six years.

“In each of her roles at Scotiabank and Tangerine, Gillian has led with a steadfast focus on growing her businesses, delivering value for clients and building her teams,” said Aris Bogdaneris, Group Head, Canadian Banking at Scotiabank. “In addition to her many accomplishments, she has left a lasting legacy at the Bank as the founder of The Scotiabank Women Initiative through which Scotiabank has stood apart from its competitors with our commitment to helping women grow their businesses, advance their careers and invest in their futures so they can succeed on their own terms.”

On her decision to retire, Ms. Riley said, “It has been an honour and a privilege to lead the Tangerine business and, together with the team, I am so proud to have built a market-leading brand in Canada that provides outstanding customer value and mobile capabilities that are best in class. I feel confident that this is the right time to pass the torch to a new leader who will continue to build on our track record of success.”

Terri-Lee Weeks joined Scotiabank in September 2021 as Executive Vice President, Retail Customer – a role in which she has successfully built client value and deepened client loyalty with retail products that drive exceptional client experience across the Canadian Bank.

“Terri-Lee is a seasoned leader with deep experience across Retail Banking, Wealth Management and Capital Markets,” said Mr. Bogdaneris. “Her wide-ranging financial services experiences, deep understanding of the Canadian retail landscape and her track record of success in scaling digital business, interactive customer experience design and transformation uniquely qualify her for this important role on our team. I have every confidence in her ability to deliver on the strong growth potential of our digital bank.”

“On behalf of all employees at Scotiabank, I would like to thank Gillian for the leadership and the mentorship she has provided both at Scotiabank and across the financial industry in Canada and we wish Terri-Lee great success in her new role,” continued Mr. Bogdaneris. 

About Scotiabank

Scotiabank’s vision is to be our clients’ most trusted financial partner, to deliver sustainable, profitable growth and maximize total shareholder return. Guided by our purpose: “for every future,” we help our clients, their families and their communities achieve success through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With assets of approximately $1.4 trillion (as at July 31, 2024), Scotiabank trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit http://www.scotiabank.com and follow us on X @Scotiabank.

SOURCE Scotiabank

https://prnmedia.prnewswire.com/news-releases/scotiabank-announces-the-appointment-of-terri-lee-weeks-as-president-and-ceo-tangerine-effective-november-1-2024-844751621.html

NEWARK, N.J., Oct. 9, 2024 /PRNewswire/ — Today, the New Jersey Board of Public Utilities (BPU) approved a settlement agreement that PSE&G had reached with BPU staff, the New Jersey Division of Rate Counsel and other parties to PSE&G’s electric and gas distribution base rate case filed in December 2023. The settlement advances PSE&G’s ability to continue providing customers with affordable, award-winning service and customer care while also providing the financial strength necessary to maintain a reliable and resilient energy grid. 

This rate case filing was required by an earlier settlement and sought recovery of prior investments made to our distribution systems, and recognition of increasing costs over time including wages and benefits. Over the last six years, PSE&G has made significant investments in strengthening our distribution system, modernizing our infrastructure to meet customer needs and other previously authorized capital expenditures that were not reflected in current rates.

More information is available in the BPU order. 

“PSE&G provides safe, affordable and reliable service to our customers, which is all the more important as people become more dependent on electricity to power their lives,” said Kim Hanemann, President and COO of PSE&G. “We remain focused on managing costs while also working to deliver the level of service our customers expect. This agreement recognizes the much-needed investments in our system that will both improve resiliency and help prepare us for the future. I want to acknowledge the BPU for their consideration and their approval of this settlement.”

This base rate increase approved by the BPU will be PSE&G’s first since 2018 and represents less than half the rate of inflation during that time. The settlement will result in a typical combined residential electric and gas customer bill increase of 7%, or $15 per month. Of note, this settlement follows the BPU’s approval of certain rate changes that just went into effect October 1, 2024, primarily a 5% reduction in PSE&G gas bills. The combined effect of the October 1 changes would reduce the bill impact from this settlement for a typical combined residential electric and gas customer to about 5%, or $11 per month. New rates will go into effect Oct. 15, 2024.

PSE&G recognizes there are customers who need assistance paying utility bills. We encourage eligible customers to take advantage of all available assistance programs including LIHEAP and the New Jersey Universal Service Fund. In 2023, over 200,000 PSE&G customers received energy assistance, totaling $218 million. Through the Fresh Start Program, $92 million in outstanding balances were forgiven.

Information on payment assistance programs is available at pseg.com/help

PSE&G also encourages customers to take advantage of our energy efficiency programs, tips and tools to help reduce energy use and manage monthly bills.

PSE&G 

Public Service Electric & Gas Co. is New Jersey’s oldest and largest gas and electric delivery public utility, as well as one of the nation’s largest utilities. PSE&G has won the ReliabilityOne® Award for superior electric system reliability in the Mid-Atlantic region for 22 consecutive years. For the second consecutive year, PSE&G is the recipient of the ENERGY STAR Partner of the Year award in the Energy Efficiency Program Delivery category. In addition, in 2023 J.D. Power named PSE&G number one in customer satisfaction with residential and business electric service in the east among large utilities. PSE&G is a subsidiary of Public Service Enterprise Group Inc., (PSEG) (NYSE:PEG), a predominantly regulated infrastructure company focused on a clean energy future and has been named to the Dow Jones Sustainability Index for North America for 16 consecutive years (www.pseg.com).

Forward-Looking Statements

Certain of the matters discussed in this release about our and our subsidiaries’ future performance, including, without limitation, future revenues, earnings, strategies, prospects, consequences, and all other statements that are not purely historical constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such statements are based on management’s beliefs as well as assumptions made by and information currently available to management. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plan,” “should,” “hypothetical,” “potential,” “forecast,” “project,” variations of such words and similar expressions are intended to identify forward-looking statements. Factors that may cause actual results to differ are often presented with the forward-looking statements themselves. Other factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are discussed in filings we make with the United States Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and subsequent reports on Form 10-Q and Form 8-K. These factors include, but are not limited to:

• any inability to successfully develop, obtain regulatory approval for, or construct transmission and distribution, and our nuclear generation projects;
• the physical, financial and transition risks related to climate change, including risks relating to potentially increased legislative and regulatory burdens, changing customer preferences and lawsuits;
• any equipment failures, accidents, critical operating technology or business system failures, natural disasters, severe weather events, acts of war, terrorism or other acts of violence, sabotage, physical attacks or security breaches, cyberattacks or other incidents that may impact our ability to provide safe and reliable service to our customers;
• any inability to recover the carrying amount of our long-lived assets;
• disruptions or cost increases in our supply chain, including labor shortages;
• any inability to maintain sufficient liquidity or access sufficient capital on commercially reasonable terms;
• the impact of cybersecurity attacks or intrusions or other disruptions to our information technology, operational or other systems;
• a material shift away from natural gas toward increased electrification and a reduction in the use of natural gas;
• failure to attract and retain a qualified workforce;
• increases in the costs of equipment, materials, fuel, services and labor;
• the impact of our covenants in our debt instruments and credit agreements on our business;
• adverse performance of our defined benefit plan trust funds and Nuclear Decommissioning Trust Fund and increases in funding requirements and pension costs;
• any inability to extend certain significant contracts on terms acceptable to us;
• development, adoption and use of Artificial Intelligence by us and our third-party vendors;
• fluctuations in, or third-party default risk in wholesale power and natural gas markets, including the potential impacts on the economic viability of our generation units;
• our ability to obtain adequate nuclear fuel supply;
• changes in technology related to energy generation, distribution and consumption and changes in customer usage patterns;
• third-party credit risk relating to our sale of nuclear generation output and purchase of nuclear fuel;
• any inability to meet our commitments under forward sale obligations and Regional Transmission Organization rules;
• the impact of changes in state and federal legislation and regulations on our business, including PSE&G’s ability to recover costs and earn returns on authorized investments;
• PSE&G’s proposed investment projects or programs may not be fully approved by regulators and its capital investment may be lower than planned;
• our ability to receive sufficient financial support for our New Jersey nuclear plants from the markets, production tax credit and/or zero emission certificates program;
• adverse changes in and non-compliance with energy industry laws, policies, regulations and standards, including market structures and transmission planning and transmission returns;
• risks associated with our ownership and operation of nuclear facilities, including increased nuclear fuel storage costs, regulatory risks, such as compliance with the Atomic Energy Act and trade control, environmental and other regulations, as well as operational, financial, environmental and health and safety risks;
• changes in federal and state environmental laws and regulations and enforcement;
• delays in receipt of, or an inability to receive, necessary licenses and permits and siting approvals; and
• changes in tax laws and regulations.

All of the forward-looking statements made in this release are qualified by these cautionary statements and we cannot assure you that the results or developments anticipated by management will be realized or even if realized, will have the expected consequences to, or effects on, us or our business, prospects, financial condition, results of operations or cash flows. Readers are cautioned not to place undue reliance on these forward-looking statements in making any investment decision. Forward-looking statements made in this release apply only as of the date of this release. While we may elect to update forward-looking statements from time to time, we specifically disclaim any obligation to do so, even in light of new information or future events, unless otherwise required by applicable securities laws.

The forward-looking statements contained in this release are intended to qualify for the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

SOURCE PSEG

https://prnmedia.prnewswire.com/news-releases/pseg-rate-case-settlement-approved-302271926.html

NEW YORK, Oct. 9, 2024 /PRNewswire/ — The Old Homestead, today, announced that they are rolling back their prices, for one night only, to 1868. America’s oldest continuously operating steakhouse will celebrate 156 years in business with a 30-cent per person dinner, featuring USDA-Prime 10-cent steaks.

“We want to give New Yorkers an exceptional classic steakhouse experience without cost being a factor. This is a chance to come out, feel the vibe of NYC, and come together over great food and celebration,” says co-owner Marc Sherry.

The 3-course 30-cent pre-fixe menu will be served at their original Meatpacking District location. The menu features The Old Homestead classic Caesar salad; a choice of Sherry Brothers 16 oz USDA Prime New York Sirloin, The Aristocrats of Tenderness Filet Mignon, or the 22 oz Gotham Rib Steak served on the bone; included sides are Grandma’s Creamed Spinach and Truffle Mac & Cheese; the dinner’s finishing touch is the World-Famous Old Homestead Cheesecake.

Reservations can be made via OpenTable (or phone: 212.242.9040) with seatings from 5 pm – 9 pm on October 21st. Walk-ins are welcome and will be seated on a first-come first-serve basis at the bar beginning at 5 pm. Gratuity and beverages are not included.

The Old Homestead has surpassed almost two centuries of culinary innovation, cultural changes…and NYC tragedies – and has become a storied landmark with a rich tapestry. The walls have absorbed conversation and storytelling; with main characters including Liza Minelli, Jackie Gleason, Art Carney, JFK, and more. Table 5, “the sports table “was home to legends like Mickey Mantle, Roger Maris, Joe Louis, and Billy Martin and is still seating sports icons today. The Old Homestead has also had the honor of hosting 4 US Presidents: James Garfield (1881), William McKinley (1901), Herbert Hoover (1931), and Harry Truman (2013). The legacy of The Old Homestead has transcended time a century and a half later – welcoming A-listers like Beyoncé, Billy Joel, Stevie Wonder, and Mike Tyson.

In its 156 years, NYC’s The Old Homestead has experienced its fair share of firsts. Owners Greg and Marc Sherry, known as “steak legends”, were the first to bring Wagyu beef into the US from Japan and will now be the first to offer guests a 10-cent steak experience that dates back over 150 years.

The Old Homestead: 

America’s oldest continuously operating steakhouse with its flagship location in NYC’s Meatpacking District and another in Atlantic City’s Borgata Hotel. Founded in 1856 by the Sherry family, the family-owned restaurant was the first to serve Wagyu Beef in the US and the originator of the “doggy bag”. For more information, visit www.theoldhomesteadsteakhouse.com.

The Old Homestead

56 9th Ave, NY, NY 10011

Website: www.theoldhomesteadsteakhouse.com

IG: @oldhomestead_steakhouse

Reservations/Open Table Link: https://www.opentable.com/r/old-homestead-steakhouse-new-york-city-new-york-2

For more information contact Elaine LaPersonerie at Wink PR (917) 930 4080 or 384619@email4pr.com.

SOURCE The Old Homestead

https://prnmedia.prnewswire.com/news-releases/10-cent-steaks-at-the-old-homestead-nyc-302271921.html

Team Moxie is the Champion of The Milk Cup, the First-Ever All-Women’s Fortnite LAN

LOS ANGELES, Oct. 9, 2024 /PRNewswire/ — Gonna Need Milk made history with the inaugural The Milk Cup Finals at Los Angeles Comic Con on Saturday, October 5. The event featured 99 of the top women’s Fortnite players who traveled to Los Angeles in an all-expenses-paid trip to compete in the first-ever all-women’s Fortnite LAN event.

The Milk Cup Finals garnered over 2.7 million stream viewers across live streams, making it one of North American esports’ most-viewed women’s tournaments.

“We were thrilled to celebrate our winning team, Team Moxie, and all the finalists in LA during this history-making weekend,” said Jen Grubb, Senior Marketing Manager at MilkPEP. “The gaming community truly showed up for these women, and we’ve been overwhelmed by the support. We’re excited to continue supporting gamers through future opportunities and through milk’s nutritional benefits as The Performance Drink of Gamers.”

The Fortnite community rallied around The Milk Cup, with top personalities like ThePeachCobbler, Bugha, and others in attendance to celebrate the competitors and present the inaugural The Milk Cup Trophy to Team Moxie which includes Moxie, Dieyuhs, and Regsita, The Milk Cup MVP award to Dieyuhs, and The Milk Cup Sportsmanship award to Kitzi. Epic Games, the creators of Fortnite, leveled up The Milk Cup Gala, a celebratory night following the competition, further endorsing the event.

Gamers often turn to energy drinks for a quick boost, but too much of these can lead to jitters and the inevitable caffeine crash, affecting both focus and performance. Dairy milk’s nutrients, including vitamin D, B12, calcium, and zinc, support focus, and its complete protein and 4 B vitamins provide sustained energy without the crash. Gonna Need Milk was proud to fuel competitors with milk—including lactose-free options for those with lactose sensitivities—helping them stay sharp and energized to dominate on the server without the crash of energy drinks.

The Milk Cup continues to be a cultural milestone in the ongoing effort to elevate women in esports, boasting the largest prize pool in North American women’s esports history. Developed in collaboration with women gamers and in partnership with Fortnite streamer ThePeachCobbler, Women of the eRena (WOTE), and produced by RaidiantGG’s all-women production team and supported by Moonrock, the event underscores Gonna Need Milk’s commitment to empowering women athletes.

The Milk Cup Goes Frozen in The Winter Split!
Gonna Need Milk is excited to announce The Milk Cup Winter Split, offering women Fortnite gamers a chance to compete in three online events to close out 2024. With $50,000 up for grabs, the Winter Split promises another shot at glory. The events will be broadcast live on Women of the eRena’s Twitch and Gonna Need Milk’s YouTube.

For updates on The Milk Cup Winter Split, please visit gonnaneedmilk.com/milkcup. For more information on The Milk Cup and the final results, follow @GonnaNeedMilk on X.

About MilkPEP:

The Milk Processor Education Program (MilkPEP), Washington, D.C., is funded by the nation’s milk companies and is dedicated to educating consumers and increasing the consumption of fluid milk. For more information, visit MilkPEP.org.

SOURCE MilkPEP

https://prnmedia.prnewswire.com/news-releases/the-milk-cup-crowns-first-champions-awarding-250-000-to-bolster-womens-esports-across-series-302271900.html

KEY POINTS

• ASUS is recognized as one of Forbes’ 2024 World’s Best Employers for the fifth consecutive year, highlighting its people-centered philosophy
• ASUS fosters innovation, creativity, and career growth, empowering employees to maximize synergies and reach their highest potential
• Forbes surveyed 300,000 employees across 50 countries, and ASUS received high rankings for its corporate image, career opportunities, and commitment to social responsibility

TORONTO, Oct. 9, 2024 /CNW/ – ASUS today proudly announced that it has been named one of Forbes’ 2024 World’s Best Employers, marking the fifth consecutive year the company has received this distinguished accolade. This recognition reaffirms ASUS’s dedication to cultivating a people-centric corporate culture that prioritizes employee development, inclusivity, and social responsibility.

Recognition as a top employer is a testament to the company’s strong corporate culture, which emphasizes collaboration, creativity, and continuous learning. Employees at ASUS benefit from a supportive and innovative environment that encourages them to contribute to meaningful global initiatives. From pioneering advancements in technology to participating in community outreach and sustainability efforts, ASUS employees are making a positive impact both within the company and beyond.

“We are deeply honored to be recognized as one of Forbes’ World’s Best Employers for the fifth consecutive year, reaffirming the strength of ASUS’s corporate culture,” said ASUS Co-CEO S.Y. Hsu. “We will continue to enhance our work environment, fostering innovation and diversity. I would also like to extend my gratitude to all of our colleagues for their trust and support as we continue to leverage our collective intelligence to drive new breakthroughs for ASUS.”

Looking forward, ASUS remains committed to furthering its mission of creating a dynamic and inclusive workplace that nurtures talent and inspires innovation. The company will continue to invest in programs and initiatives that support the professional and personal growth of its employees, ensuring that ASUS remains a preferred employer of choice in the competitive global market.

The Forbes’ World’s Best Employers list, compiled in partnership with Statista, is based on a global survey of employees who rate their willingness to recommend their employers to friends and family, as well as their satisfaction with various workplace attributes, including working conditions, diversity, and opportunities for growth. The continued presence of ASUS on this prestigious list highlights the company’s commitment to fostering an environment where employees are empowered to thrive and achieve their fullest potential.

Notes to Editors

ASUS Pressroom: http://press.asus.com

ASUS Canada Facebook: https://www.facebook.com/asuscanada/

ASUS Canada Instagram: https://www.instagram.com/asus_ca

ASUS Canada YouTube: https://ca.asus.click/youtube

ASUS Global X (Twitter): https://www.x.com/asus

About ASUS

ASUS is a global technology leader that provides the world’s most innovative and intuitive devices, components, and solutions to deliver incredible experiences that enhance the lives of people everywhere. With its team of 5,000 in-house R&D experts, the company is world-renowned for continuously reimagining today’s technologies. Consistently ranked as one of Fortune’s World’s Most Admired Companies, ASUS is also committed to sustaining an incredible future. The goal is to create a net zero enterprise that helps drive the shift towards a circular economy, with a responsible supply chain creating shared value for every one of us.

SOURCE ASUS Computer International

https://prnmedia.prnewswire.com/news-releases/asus-achieves-forbes-world-s-best-employers-list-for-fifth-consecutive-year-886323471.html

PORTLAND, Ore., Oct. 9, 2024 /PRNewswire/ — This upcoming Saturday, October 12th, 2024, activists around the world are joining together to celebrate Period Action Day (presented by The Aerie Real Foundation) by raising awareness and taking action against period poverty and stigma. Celebrated every second Saturday in October, this annual day of action was created by advocacy organization PERIOD. in 2019.

This year, activists from PERIOD. chapters and nonprofit community partners are hosting over 60 events around the world, including menstrual product drives, rallies and educational events, to demand accessible period products for students in schools and an end to the discriminatory sales tax on period products, which still exists in 20 United States.

Nearly 1 in 4 students in the U.S. struggle to afford period products. That unfortunate reality is even more prevalent for adults, where nearly 1 in 3 people cannot afford products. Although classified as medical necessities, accessibility and affordability of menstrual products is often overlooked. The same is true for comprehensive menstrual health education. The biological process of menstruation is shared by over half of the American population and should be prioritized as such through state and federal policies.

“This Period Action Day, we call on policymakers to listen to the demands of youth, and make period products less expensive and easily available. With only days to go before a landmark election, the status quo has to change. 20 states still tax period products and only 10 require and fund period products in all public schools,” says Michela Bedard, Executive Director at PERIOD., “The global menstrual movement is bigger and more prepared than ever before to end period poverty and stigma in our lifetime. By the next US presidential election, we aim to see the repeal of the unfair tax on menstrual products in all 50 states.”

“We launched the Aerie Real Foundation two years ago with a mission to support causes that build confidence in women. In addition to the much-needed advocacy and education that PERIOD. provides across the world, the most remarkable component of this great work is that it’s predominantly student-led,” said Jennifer Foyle, President and Executive Creative Director, American Eagle & Aerie. “Through initiatives like Period Action Day, we are incredibly proud to help create systemic change by broadening access to menstrual products and by equipping young women with the knowledge and confidence to promote body literacy in their communities.”

PERIOD. calls for individuals and organizations to take action against period poverty this Saturday by donating period products (online or in-person), signing a petition to abolish the “tampon tax”, and contacting your state representatives to support policies that further access to period products in schools, shelters, prisons, and more. All resources to take action and learn more can be found at periodactionday.com.

About PERIOD.: PERIOD. is a global advocacy organization founded in 2014 working to end period poverty and stigma through advocacy, education and service with hundreds of chapters around the world. The chapters are primarily led by students who work to end period poverty in their own communities. PERIOD. helps promote laws and policies that make period products affordable and accessible, creates original menstrual health curriculum and resources, and distributes millions of period products annually. Learn more at period.org

About the Aerie Real Foundation: The Aerie Real Foundation works to build confidence in young women, foster an inclusive community, and protect our planet to make the world a better place for all. By donating to national philanthropic organizations, giving grants to community programs, and providing educational resources, the Aerie Real Foundation is investing in making the world a more positive place for this generation and generations to come.

For questions, contact Emily Swanigan at media@period.org.

SOURCE PERIOD.

https://prnmedia.prnewswire.com/news-releases/youth-activists-across-the-globe-celebrate-period-action-day-2024—presented-by-aerie-real-foundation-302271931.html